Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial

Dewan, 2018, Estimating the global incidence of traumatic brain injury, J Neurosurg, 1, 1

Perel, 2009, Intracranial bleeding in patients with traumatic brain injury: a prognostic study, BMC Emerg Med, 9, 15, 10.1186/1471-227X-9-15

Oertel, 2002, Progressive hemorrhage after head trauma: predictors and consequences of the evolving injury, J Neurosurg, 96, 109, 10.3171/jns.2002.96.1.0109

Narayan, 2008, Progression of traumatic intracerebral hemorrhage: a prospective observational study, J Neurotrauma, 25, 629, 10.1089/neu.2007.0385

2010, Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial, Lancet, 376, 23, 10.1016/S0140-6736(10)60835-5

2011, The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial, Lancet, 377, 1096, 10.1016/S0140-6736(11)60278-X

Gayet-Ageron, 2018, Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40 138 bleeding patients, Lancet, 391, 125, 10.1016/S0140-6736(17)32455-8

Zhang, 2018, Prognostic role of D-dimer level upon admission in patients with traumatic brain injury, Medicine, 97

Perel, 2012, CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage) intracranial bleeding study: the effect of tranexamic acid in traumatic brain injury - a nested randomised, placebo-controlled trial, Health Technol Assess, 16, 1, 10.3310/hta16130

Yutthakasemsunt, 2013, Tranexamic acid for patients with traumatic brain injury: a randomized, double-blinded, placebo-controlled trial, BMC Emergency Medicine, 13, 20, 10.1186/1471-227X-13-20

Roberts, 2018, Tranexamic acid for significant traumatic brain injury (the CRASH-3 trial): statistical analysis plan for an international, randomised, double-blind, placebo-controlled trial, Wellcome Open Res, 3, 86, 10.12688/wellcomeopenres.14700.2

Hijazi, 2015, Endogenous plasminogen activators mediate progressive intracranial hemorrhage after traumatic brain injury, Blood, 125, 2558, 10.1182/blood-2014-08-588442

Medcalf, 2015, The traumatic side of fibrinolysis, Blood, 125, 2457, 10.1182/blood-2015-02-629808

Dewan, 2012, CRASH-3—tranexamic acid for the treatment of significant traumatic brain injury: study protocol for an international randomized, double-blind, placebo-controlled trial, Trials, 13, 87, 10.1186/1745-6215-13-87

Rogers, 1995, Systematic underestimation of treatment effects as a result of diagnostic test inaccuracy: implications for the interpretation and design of thromboprophylaxis trials, Thromb Haemost, 73, 167, 10.1055/s-0038-1653746

Roberts, 2014, Mechanism of action of tranexamic acid in bleeding trauma patients: an exploratory analysis of data from the CRASH-2 trial, Critical Care, 18, 685, 10.1186/s13054-014-0685-8